Chong Kun Dang Holdings
8, Chungjeong-ro, Seodaemun-gu, Seoul, Seoul-t'ukpyolsi, 03742, South Korea
Overview
Chong Kun Dang manufactures pharmaceutical raw materials that improve human health and prolong life. produces and sells drugs and pharmaceutical active components. It provides over-the-counter medicines, prescription medications, dietary supplements, and consumer health items.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Business Intelligence
- Consulting
Investment portfolio
- BIORCHESTRA
Participated · Series C · Feb 2022
Biorchestra is an RNA therapeutics company based in Daejeon, South Korea, and Cambridge, Massachusetts. It develops RNA-based therapeutics using a BMD platform that can control microRNAs which regulate multiple messenger RNAs involved in disease. The company has developed a proprietary drug delivery system (BDDS™) for commercial drug development and reports IV-delivered ASO knock-down efficacy in cortex, hippocampus, striatum and spinal cord. Leadership includes CEO Branden (Jinhyeob) Ryu, CMO and US President Dr. Louis O’Dea, and CFO Young-Gil Kim. Biorchestra plans to use new funding to expand R&D and its product pipeline, complete a GMP facility, and initiate nonclinical toxicology programs. The company raised $45M in Series C financing to support these activities.
Team
Jang-han Rhee
CEO